Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 09.11.2026 1 AJR Am J Roentgenol 1 Am J Epidemiol 1 Ann Oncol 1 Ann Thorac Surg 5 BMC Cancer 2 Br J Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Cancer Sci 1 Clin Cancer Res 1 Clin Exp Metastasis 5 Clin Lung Cancer 1 Eur J Cancer 2 Eur J Cardiothorac Surg 2 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Invest 3 J Clin Oncol 13 J Thorac Oncol 2 JAMA Oncol 2 Lung Cancer 1 Nat Med 3 Oncogene 1 Oncol Rep 1 Oncologist 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LI Y, Li X, Long Y, Zheng Y, et al
   Attenuation- and Entropy-Based Habitat Imaging for High-Risk Features in Lung Adenocarcinoma Presenting as a Part-Solid Nodule on CT: A Multicenter Study.
   AJR Am J Roentgenol. 2026 Jun 17. doi: 10.2214/AJR.26.34886.
   PubMed         Abstract available
   
   

   
   Am J Epidemiol

2. CHIU WM, Tsai DR, Chiang CJ, Lee WC, et al
   Evaluating risk prediction models: the predictiveness curve and its geometric summaries.
   Am J Epidemiol. 2026;195:2899-2906.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. WAKELEE HA, Ahn MJ, Bradley J, Popat S, et al
   SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation.
   Ann Oncol. 2026;37:1513-1523.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

4. FECZKO A, Abdelsattar ZM, Bonnell L, Chang SC, et al
   The Society of Thoracic Surgeons 2026 Long-term Risk Models for Lung Cancer Resection.
   Ann Thorac Surg. 2026 Nov 5:S0003-4975(26)01097.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. TASDEMIR A, Karaman H, Kiremit N, Gunes ML, et al
   PD-L1 expression across molecular driver subsets in non-small cell lung carcinoma: a 299-case real-world thoracic oncology cohort.
   BMC Cancer. 2026;26:1331.
   PubMed         Abstract available
   
   
6. WANG Z, Xu Z, Wang L, Sun M, et al
   Patterns of failure in metastatic ALK-positive NSCLC treated with crizotinib: implications for consolidative stereotactic body radiotherapy.
   BMC Cancer. 2026;26:1343.
   PubMed         Abstract available
   
   
7. CARBONELL C, Ding PQ, Adegbulugbe AA, O'Sullivan DE, et al
   Patient-physician sex concordance and real-world disparities in cancer treatment practices and outcomes in medical oncology.
   BMC Cancer. 2026;26:1355.
   PubMed         Abstract available
   
   
8. QIAO H, Han X, Zhao L, Tang H, et al
   Pretreatment serum IRAK4 and NLRP3 concentrations, their combined score, and overall survival in non-small cell lung cancer: a retrospective single-center cohort study.
   BMC Cancer. 2026;26:1354.
   PubMed         Abstract available
   
   
9. ZHANG R, Chen X, Li N, Peng M, et al
   Integrated analysis identifies an aging-related prognostic signature for lung adenocarcinoma.
   BMC Cancer. 2026;26:1347.
   PubMed         Abstract available
   
   

   
   Br J Cancer

10. ASHOURI K, Sun F, Krause H, Elliott A, et al
    Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma.
    Br J Cancer. 2026;135:1686-1693.
    PubMed         Abstract available
    
    
11. XIE H, Xu C, Zhou B, Cheng F, et al
    CTPS1 promotes lung adenocarcinoma progression as a targetable vulnerability.
    Br J Cancer. 2026;135:1694-1704.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

12. LENG S
    Opium Consumption and Lung Cancer: From Self-reported Use to Exposure Biomarkers.
    Cancer Epidemiol Biomarkers Prev. 2026;35:1801-1803.
    PubMed         Abstract available
    
    

    
    Cancer Lett

13. LONG Y, Liu Y, Miao K, Xiao D, et al
    Immune checkpoint inhibitor therapy in COPD-concomitant lung cancer: A review of efficacy outcomes and mechanistic insights.
    Cancer Lett. 2026;663:218933.
    PubMed         Abstract available
    
    

    
    Cancer Sci

14. LI N, Wang R, Zhang W, Shao Z, et al
    Epidemiological and Prognostic Differences in Malignant Mesothelioma Between Eastern China and SEER Database.
    Cancer Sci. 2026;117:3146-3159.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. CARRASQUILLA SD, Bi Y, Gu W, Ayyoub A, et al
    Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations.
    Clin Cancer Res. 2026 Nov 6. doi: 10.1158/1078-0432.CCR-26-1022.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

16. JEONG JU, Yoo GS, Lee JH, Chan Ahn Y, et al
    Oncologic efficacy and safety of stereotactic body radiotherapy for oligometastatic non-small cell lung cancer: a systemic meta-analysis.
    Clin Exp Metastasis. 2026;43:62.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

17. JAYAMANNE D, Chan J, Mohan R, Dave S, et al
    Pretreatment FDG-PET Biomarkers Predict Regional and Distant Failure but Not Local Recurrence Following Modern Use of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:16-24.
    PubMed         Abstract available
    
    
18. NAMBIRAJAN A, Yadav K, Sahu S, Bhagat S, et al
    Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting.
    Clin Lung Cancer. 2026;27:25-36.
    PubMed         Abstract available
    
    
19. KUON J, Blasi M, Bozorgmehr F, Kokowski K, et al
    Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416).
    Clin Lung Cancer. 2026;27:1-11.
    PubMed         Abstract available
    
    
20. GOLDMAN JW, Riess JW, Cho BC, Goldberg SB, et al
    Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD.
    Clin Lung Cancer. 2026;27:52-61.
    PubMed         Abstract available
    
    
21. KRISHNA A, Reich A, Lebovic G, Lubwama R, et al
    Assessment of Prognostic Value of CEACAM5 Expression Using Archival Tissue and Real-World Evidence of Metastatic Patients with NSCLC in United States.
    Clin Lung Cancer. 2026;27:25-33.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

22. DE GIORGI V, Perillo G, Cecchi G, Fazzari F, et al
    Letter Re: Assessing the magnitude of surveillance bias in prostate cancer, melanoma and lung cancer.
    Eur J Cancer. 2026;249:117078.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

23. CAMPISI A, Fang W, Dell'Amore A, Chen Y, et al
    Anatomical Segmentectomy Versus Lobectomy for cT1N0M0 NSCLC Upstaged to pT2aN0M0 by Occult Visceral Pleural Invasion: A Multicentre Cohort Study.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
24. BRUNELLI A
    Beyond Tumour Size: Integrating Tumour Biology and Technical Quality to Select the Extent of Resection in Early-Stage NSCLC.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    

    
    Int J Cancer

25. WU D, Chen B, Chen X, Wu X, et al
    Smoking, Solid Fuel Use for Cooking, and Cancer Mortality: A Prospective Cohort Study in Southwestern China.
    Int J Cancer. 2027;160:31-43.
    PubMed         Abstract available
    
    
26. LI J, Yin X, Zhao G, Liu X, et al
    Fruit and Vegetable Intake in Relation to the Risks of Lung, Colorectal, Stomach, and Overall Cancers in China: A Prospective Cohort Study.
    Int J Cancer. 2027;160:98-109.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

27. DUIJM DM, Cammareri E, Granton DPV, Schillemans W, et al
    High-dose reirradiation of in-field recurrence lung cancer in the THOrax (RETHO): toxicity analysis of a prospective trial.
    Int J Radiat Oncol Biol Phys. 2026 Nov 2:S0360-3016(26)04386.
    PubMed         Abstract available
    
    

    
    J Clin Invest

28. QI X, Cui D, Li X, Fu W, et al
    Targeting N-acetyltransferase 10 reprograms Treg function to enhance anti-PD-1 immunotherapy sensitivity in murine lung tumors.
    J Clin Invest. 2026;136:e189034.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

29. STILES BM
    When Practice Outpaces Evidence: Comparative Evidence for Stereotactic Ablative Radiotherapy Versus Surgical Resection for Stage I Non?Small Cell Lung Cancer.
    J Clin Oncol. 2026 Nov 3:JCO2601859. doi: 10.1200/JCO-26-01859.
    PubMed        
    
    
30. KAGENAAR E, Lugo-Palacios DG, Aggarwal A, Hutchings A, et al
    Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non-Small Cell Lung Cancer: An Emulated Target Trial.
    J Clin Oncol. 2026 Nov 2:JCO2600399. doi: 10.1200/JCO-26-00399.
    PubMed         Abstract available
    
    
31. MONACA F, Randulfe I, Heymach JV, Zhou C, et al
    P-Loop/alphaC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.
    J Clin Oncol. 2026;44:3163-3173.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

32. TANG H, Deng C, Cao H, Fu F, et al
    The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification.
    J Thorac Oncol. 2026;21:103965.
    PubMed         Abstract available
    
    
33. BARAMIDZE A, Makharadze T, Gogishvili M, Melkadze T, et al
    Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.
    J Thorac Oncol. 2026;21:103980.
    PubMed         Abstract available
    
    
34. SUZUKI S, Parikh K, Tolosa E, Wu KL, et al
    Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement.
    J Thorac Oncol. 2026;21:103993.
    PubMed         Abstract available
    
    
35. UDAGAWA H, Shibata Y, Nilsson MB, Nishii K, et al
    Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance.
    J Thorac Oncol. 2026;21:103991.
    PubMed         Abstract available
    
    
36. LI Z, Yao B, Huang C, Xie C, et al
    Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial.
    J Thorac Oncol. 2026;21:104062.
    PubMed         Abstract available
    
    
37. WEI Q, Wang Y, Hou T, Wang Q, et al
    Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights From a Large-Scale Real-World Chinese Cohort.
    J Thorac Oncol. 2026;21:104077.
    PubMed         Abstract available
    
    
38. MANTZ L, Mercaldo ND, Peterson J, Abadi P, et al
    Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue.
    J Thorac Oncol. 2026;21:104078.
    PubMed         Abstract available
    
    
39. ROSS JS, Lee J, Ortiz E, Yildirim O, et al
    Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid.
    J Thorac Oncol. 2026;21:104135.
    PubMed         Abstract available
    
    
40. JOSHI U, Zhang B, Thompson ZJ, Desai A, et al
    Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from the ONWARD consortium.
    J Thorac Oncol. 2026 Nov 4:106243. doi: 10.1016/j.jtho.2026.106243.
    PubMed         Abstract available
    
    
41. XIONG A, Meng X, Li X, Zhang Y, et al
    Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion-positive non-small cell lung cancer phase 2 study.
    J Thorac Oncol. 2026 Nov 5:106244. doi: 10.1016/j.jtho.2026.106244.
    PubMed         Abstract available
    
    
42. ADJEI AA
    The Price of Progress in Lung Cancer: Global Disparities, Drug Costs, and the Challenge of Equitable Access.
    J Thorac Oncol. 2026;21:106120.
    PubMed        
    
    
43. MULLIN M, Tremblay A
    Cytisine for Smoking Cessation in Lung Cancer Screening Participants: Promise, Caveats, and a Path Forward.
    J Thorac Oncol. 2026;21:104175.
    PubMed        
    
    
44. XIE B, Ali H, Yang J, Nadeem U, et al
    Central Adiposity, Confounding Medications, and the Reinterpretation of the "Obesity Paradox" in Lung Cancer Risk.
    J Thorac Oncol. 2026;21:104120.
    PubMed        
    
    

    
    JAMA Oncol

45. ZHOU F, Wang L, Bai J, Yang F, et al
    HB0025 With Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2026 Nov 5. doi: 10.1001/jamaoncol.2026.4455.
    PubMed         Abstract available
    
    
46. D'AIELLO A, Halmos B
    HB0025, a Novel Anti-PD-L1/VEGF Trap Bispecific Antibody Plus Chemotherapy in Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2026 Nov 5. doi: 10.1001/jamaoncol.2026.4373.
    PubMed        
    
    

    
    Lung Cancer

47. AYDIN AA, Yesilcay HB
    Rethinking the clock: Is treatment-free interval truly predictive of platinum sensitivity in small-cell lung cancer?
    Lung Cancer. 2026 Nov 1:109645. doi: 10.1016/j.lungcan.2026.109645.
    PubMed        
    
    
48. ZHANG J, Chen W, Mi L, Sun Y, et al
    Adverse events in placebo arms of phase III lung cancer trials: a systematic review and meta-analysis.
    Lung Cancer. 2026;222:109675.
    PubMed         Abstract available
    
    

    
    Nat Med

49. ZHAO X, Zhang B, Li C, Zhang L, et al
    Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial.
    Nat Med. 2026 Nov 4. doi: 10.1038/s41591-026-04745.
    PubMed         Abstract available
    
    

    
    Oncogene

50. YANG Y, Liu T, Cho CY, Liu X, et al
    Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses.
    Oncogene. 2026;45:4990-5001.
    PubMed         Abstract available
    
    
51. AIHEMAITI Y, Ren Q, Jiang X, Wushaying K, et al
    Phosphorylation of IRS4 at YY111/112 promotes LUSC progression via PI3K/AKT pathway activation.
    Oncogene. 2026;45:5018-5034.
    PubMed         Abstract available
    
    
52. LIU X, Wang Z, Zou X, Chen T, et al
    KDM4A drives TGCT metastasis by inducing focal adhesion disassembly via STAT1-mediated CCL3 transcriptional activation.
    Oncogene. 2026;45:4888-4901.
    PubMed         Abstract available
    
    

    
    Oncol Rep

53. WU Y, Ma N, Wang N, Liu X, et al
    Resveratrol induces ferroptosis to repress malignant progression of lung cancer cells.
    Oncol Rep. 2027;57:2.
    PubMed         Abstract available
    
    

    
    Oncologist

54. LIU YJ, Desai PA, Khurshid H, Chiang AC, et al
    Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy.
    Oncologist. 2026 Nov 4:oyag434. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

55. LE DT, Szabo D, Aranyi S, Miko M, et al
    Assessment of algorithmic performance in PET-CT segmentation of solitary lung tumors.
    PLoS One. 2026;21:e0360849.
    PubMed         Abstract available
    
    
56. LIU T, Song D, Chen J, Yao J, et al
    Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis.
    PLoS One. 2026;21:e0361953.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum